Matrix metalloproteinases and small artery remodeling

Drug Discovery Today: Disease Models

Volumn 8, Issue 1, 2011, Pages 21-28

  Martinez Lemus, Luis A ^a,b   Galiñanes, Edgar Luis ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ARGINYLGLYCYLASPARTIC ACID; BATIMASTAT; DOXYCYCLINE; EDETIC ACID; FN 439; GELATINASE A; GELATINASE B; ILOMASTAT; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; REACTIVE OXYGEN METABOLITE; TEMPOL; UNCLASSIFIED DRUG;

ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL; CAROTID ARTERY; ENZYME ACTIVITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; EX VIVO STUDY; EXTRACELLULAR MATRIX; HYPERTENSION; ILIAC ARTERY; KNOCKOUT MOUSE; MESENTERIC ARTERY OCCLUSION; MOUSE; NONHUMAN; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RABBIT; RAT; RENOVASCULAR HYPERTENSION; RESISTANCE BLOOD VESSEL; SPONTANEOUSLY HYPERTENSIVE RAT; SWINE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 82455167813     PISSN: None     EISSN: 17406757     Source Type: Journal    
DOI: 10.1016/j.ddmod.2011.06.002     Document Type: Review

References (73)

1. Mathiassen, O. N. et al. (2007) Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J. Hypertens. 25, 1021-1026 (Pubitemid 46573121)
2. Rizzoni, D. et al. (2003) Prognostic significance of small-artery structure in hypertension. Circulation 108, 2230-2235 (Pubitemid 37363040)
3. Mulvany, M. J. et al. (1996) Vascular remodeling. Hypertension 28, 505-506 (Pubitemid 26298571)
4. Raffetto, J. D. and Khalil, R. A. (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75, 346-359 (Pubitemid 350298459)
5. Hao, L. et al. (2004) Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res. 94, 68-76 (Pubitemid 38064100)
6. Rodrigues, S. F. et al. (2010) Matrix metalloproteinases cleave the beta2- adrenergic receptor in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 299, H25-H35
7. Yang, Y. et al. (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 27, 697-709 (Pubitemid 46474608)
8. Kandasamy, A. D. et al. (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc. Res. 85, 413-423
9. Yang, Y. et al. (2010) Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J. Neurochem. 112, 134-149
10. Martinez-Lemus, L. A. et al. (2009) The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology (Bethesda) 24, 45-57
11. Schiffrin, E. L. (2004) Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am. J. Hypertens. 17 (Pt 1), 1192-1200 (Pubitemid 40029420)
12. DeLano, F. A. and Schmid-Schonbein, G. W. (2008) Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension 52, 415-423
13. Tran, E. D. et al. (2010) Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J. Vasc. Res. 47, 423-431
14. Friese, R. S. et al. (2009) Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin. Exp. Hypertens. 31, 521-533
15. Wang, X. et al. (2009) Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonistinduced hypertension and cardiac hypertrophy. Circulation 119, 2480-2489
16. Fernandez-Patron, C. et al. (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ. Res. 85, 906-911 (Pubitemid 29534165)
17. Fernandez-Patron, C. et al. (2000) Vascular matrix metalloproteinase-2- dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ. Res. 87, 670-676
18. Christensen, K. L. and Mulvany, M. J. (2001) Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J. Hypertens. 19, 1001-1006 (Pubitemid 32493631)
19. Zhou, M. S. et al. (2005) Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension. J. Hypertens. 23, 1737-1743
20. Dao, H. H. et al. (2001) Transient involvement of endothelin in hypertrophic remodeling of small arteries. J. Hypertens. 19, 1801-1812 (Pubitemid 32924946)
21. Pistea, A. et al. (2008) Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: role of transglutaminases. J. Vasc. Res. 45, 10-18 (Pubitemid 350275239)
22. Odenbach, J. et al. (2011) MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 57, 123-130
23. Seomun, Y. et al. (2008) MMP-14 mediated MMP-9 expressionis involved in TGF-beta1-induced keratinocyte migration. J. Cell. Biochem. 104, 934-941 (Pubitemid 351830841)
24. Chang, D. I. et al. (2003) Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 23, 1408-1419
25. Castro, M. M. et al. (2010) Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol. 29, 194-201
26. Flamant, M. et al. (2007) Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 50, 212-218 (Pubitemid 46986043)
27. Lehoux, S. et al. (2004) Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 109, 1041-1047 (Pubitemid 38282859)
28. Abdul-Hussien, H. et al. (2009) Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J. Vasc. Surg. 49, 741-749
29. Keeling, W. B. et al. (2005) An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms. Vasc. Endovasc. Surg. 39, 457-464 (Pubitemid 41790136)
30. Krishna, S. M. et al. (2010) Genetic and epigenetic mechanisms and their possible role in abdominal aortic aneurysm. Atherosclerosis 212, 16-29
31. Longo, G. M. et al. (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110, 625-632
32. Ota, R. et al. (2009) Roles of matrix metalloproteinases in flow-induced outward vascular remodeling. J. Cereb. Blood Flow Metab. 29, 1547-1558
33. Nuki, Y. et al. (2009) Roles of macrophages in flow-induced outward vascular remodeling. J. Cereb. Blood Flow Metab. 29, 495-503
34. Coussens, L. M. et al. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (Pubitemid 34270240)
35. Castro, M. M. et al. (2008) Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198, 320-331 (Pubitemid 351707391)
36. Castro, M. M. et al. (2009) Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic. Biol. Med. 46, 1298-1307
37. Touyz, R. M. and Briones, A. M. (2011) Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens. Res. 34, 5-14
38. Pistea, A. et al. (2005) Flow inhibits inward remodeling in cannulated porcine small coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 289, H2632-H2640 (Pubitemid 41698580)
39. Grote, K. et al. (2003) Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD (P) H oxidase-derived reactive oxygen species. Circ. Res. 92, e80-e86
40. Siwik, D. A. and Colucci, W. S. (2004) Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail. Rev. 9, 43-51 (Pubitemid 38196076)
41. Martinez-Lemus, L. A. et al. (2011) Inward remodeling of resistance arteries requires reactive oxygen species-dependent activation of matrix metalloproteinases. Am. J. Physiol. Heart Circ. Physiol. 300, H2005-H2015
42. Chesler, N. C. et al. (1999) Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am. J. Physiol. 277 (Pt 2), H2002-H2009
43. Lucchesi, P. A. et al. (2004) Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation 110, 3587-3593 (Pubitemid 39612575)
44. Asanuma, K. et al. (2003) Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 284, H1778-H1784 (Pubitemid 36460794)
45. Girardot, D. et al. (2003) ERK1/2-mediated vasoconstriction normalizes wall stress in small mesenteric arteries during NOS inhibition in vivo. J. Cardiovasc. Pharmacol. 42, 339-347 (Pubitemid 37071689)
46. Bakker, E. N. et al. (2002) Inward remodeling follows chronic vasoconstriction in isolated resistance arteries. J. Vasc. Res. 39, 12-20 (Pubitemid 34158355)
47. Hill, M. A. et al. (2003) Delayed arteriolar relaxation after prolonged agonist exposure: functional remodeling involving tyrosine phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 285, H849-H856 (Pubitemid 36885919)
48. Martinez-Lemus, L. A. (2008) Persistent agonist-induced vasoconstriction is not required for angiotensin II to mediate inward remodeling of isolated arterioles with myogenic tone. J. Vasc. Res. 45, 211-221 (Pubitemid 351543145)
49. Bakker, E. N. et al. (2005) Small artery remodeling depends on tissue-type transglutaminase. Circ. Res. 96, 119-126 (Pubitemid 40095761)
50. Luchtefeld, M. et al. (2005) Angiotensin II induces MMP-2 in a p47phoxdependent manner. Biochem. Biophys. Res. Commun. 328, 183-188 (Pubitemid 40164653)
51. Fortuno, A. et al. (2009) Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension 54, 744-750
52. Carlson, B. E. and Secomb, T. W. (2005) A theoretical model for the myogenic response based on the length-tension characteristics of vascular smooth muscle. Microcirculation 12, 327-338 (Pubitemid 40872925)
53. Martinez-Lemus, L. A. et al. (2004) Acute mechanoadaptation of vascular smoothmuscle cellsin responsetocontinuous arteriolar vasoconstriction: implications for functional remodeling. FASEB J. 18, 708-710
54. Bendeck, M. P. et al. (1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 75, 539-545 (Pubitemid 24256415)
55. Bendeck, M. P. et al. (2002) Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am. J. Pathol. 160, 1089-1095 (Pubitemid 34224595)
56. Margolin, L. et al. (2002) Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha (v) beta (3) receptor blockade. Atherosclerosis 163, 269-277 (Pubitemid 34615817)
57. Courtman, D. W. et al. (2004) Inward remodeling of the rabbit aorta is blocked by the matrix metalloproteinase inhibitor doxycycline. J. Vasc. Res. 41, 157-165 (Pubitemid 38478872)
58. Furmaniak-Kazmierczak, E. et al. (2007) Formation of extracellular matrixdigesting invadopodia by primary aortic smooth muscle cells. Circ. Res. 100, 1328-1336 (Pubitemid 46742923)
59. Jin, Y. J. et al. (2011) Fibronectin and vitronectin induce AP-1-mediated matrix metalloproteinase-9 expression through integrin alpha (5) beta (1)/alpha (v) beta (3)-dependent Akt, ERK and JNK signaling pathways in human umbilical vein endothelial cells. Cell. Signal. 23, 125-134
60. Meng, D. et al. (2007) Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species. Free Radic. Biol. Med. 42, 1651-1660 (Pubitemid 46617145)
61. Hur, G. Y. et al. (2009) Tissue transglutaminase can be involved in airway inflammation of toluene diisocyanate-induced occupational asthma. J. Clin. Immunol. 29, 786-794
62. Lee, Z. W. et al. (2003) Activation of in situ tissue transglutaminase by intracellular reactive oxygen species. Biochem. Biophys. Res. Commun. 305, 633-640
63. Yi, S. J. et al. (2006) [Ca (2+)]-dependent generation of intracellular reactive oxygen species mediates maitotoxin-induced cellular responses in human umbilical vein endothelial cells. Mol. Cells 21, 121-128
64. Langille, B. L. and Dajnowiec, D. (2005) Cross-linking vasomotor tone and vascular remodeling: a novel function for tissue transglutaminase? Circ. Res. 96, 9-11 (Pubitemid 40095749)
65. Janiak, A. et al. (2006) Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway. Mol. Biol. Cell 17, 1606-1619 (Pubitemid 44017561)
66. Akimov, S. S. et al. (2000) Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J. Cell Biol. 148, 825-838
67. Bendeck, M. P. et al. (2000) Smooth muscle cell matrix metalloproteinase production is stimulated via alpha (v) beta (3) integrin. Arterioscler. Thromb. Vasc. Biol. 20, 1467-1472 (Pubitemid 30353875)
68. Bendeck, M. P. et al. (1996) Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ. Res. 78, 38-43 (Pubitemid 26004118)
69. De Smet, B. J. et al. (2000) Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 101, 2962-2967 (Pubitemid 30415888)
70. Sierevogel, M. J. et al. (2001) Oral matrix metalloproteinase inhibition and arterial remodeling after balloon dilation: an intravascular ultrasound study in the pig. Circulation 103, 302-307 (Pubitemid 32095419)
71. Sierevogel, M. J. et al. (2002) Matrix metalloproteinase inhibition reduces adventitial thickening and collagen accumulation following balloon dilation. Cardiovasc. Res. 55, 864-869
72. Bouvet, C. et al. (2005) Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45, 432-437 (Pubitemid 40315814)
73. Dumont, O. et al. (2007) Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-induced remodeling of rat resistance arteries. Arterioscler. Thromb. Vasc. Biol. 27, 317-324 (Pubitemid 46143046)